Aim: Peripheral arterial disease (PAD), particularly critical limb ischemia (CLI), is a severe cause of amputation and mortality. More than 50% of diabetic patients with CLI die within four to five years. The development of novel stem cell therapies may bring new hope to these patients. We aimed to assess the efficacy of autologous bone marrow cell therapy for treating CLI using a meta-analysis. Methods: We searched the literature in PubMed, the Cochrane Central Registry of Controlled Trials, the Elsevier database and EBSCO for trials of autologous cell therapy in patients with severe PAD published before October 30, 2013. We chose objective clinical endpoints to assess the efficacy of therapy in the meta-analysis, including changes in the ankle-brachial index (ABI), transcutaneous oxygen tension (TcO2), pain scale (0-10 scale) and amputation-free survival (AFS). Results: Thirty-one articles reporting clinical trials involving a total of 1,214 patients treated with bone marrow stem cell-based therapy were collected for the meta-analysis, in which the randomized controlled trials (RCTs) and other trials (non-RCTs) were classified into two groups. Regarding the efficacy of stem cell therapy, the ABI showed significant increases (P＜0.05) at 12 , 24 and 48 weeks after therapy in the non-RCT and RCT groups, but not after four to eight weeks in the non-RCT group. The TcO2 values also increased in the RCT group at four to eight weeks after therapy and 24 weeks after therapy (P＜0.001) and in the non-RCT group at four to eight weeks after therapy (P = 0.01), although no significant increases were observed in the RCT group at 12 weeks after therapy or the non-RCT group at 24 weeks after therapy. Meanwhile, pain was significantly reduced (P＜0.05) at four to eight weeks and 24 weeks after therapy in both the non-RCT and RCT groups, but not at four to eight weeks or 12 weeks after therapy in the RCT group. In addition, the long-term clinical trials demonstrated that the AFS rate improved after therapy with bone marrow stem cells (one-year AFS, P＜0.00001; three-year AFS, P = 0.0003).
Introduction
Peripheral arterial disease (PAD) is a common syndrome worldwide, whose incidence is increasing yearly in association with changes in diet and the aging of the population. PAD is consistently associated with a relatively high rate of morbidity and mortality due to the effects of symptoms such as claudica-emia." The search sources included the PubMed database, the Cochrane Central Registry of Controlled Trials, the Elsevier database and EBSCO. Papers published in English and Chinese were included. However, we excluded any case reports and studies using animals or cell lines.
Data Collection and Clinical Endpoints
We performed a meta-analysis of all eligible studies (randomized controlled trials and other trials, divided into two groups for a separate analysis) and selected objective clinical endpoints to assess the efficacy of therapy, such as changes in the ankle-brachial index (ABI), transcutaneous oxygen tension (TcO2), pain scale (0-10 scale) and amputation-free survival (AFS). We collected data regarding safety issues, taking into consideration the incidence of adverse events, including death, recurrence and fever, with different follow-up times.
Statistical Analysis
The analysis was performed using the Review Manager Version 5.0 software program (Nordic Cochran Centre, Copenhagen, Denmark). In order to estimate the treatment effects, the outcomes were calculated as continuous variables and binary variables with respective 95% confidence intervals (CIs). Taking inherited heterogeneity into consideration, we adopted a random-effects model. The degree of heterogeneity across the trials was estimated according to the I 2 statistics. A P value of ≤ 0.05 was considered to be significant, and the SPSS version 17.0 software program was used to analyze the data according to the chi-square test with likelihood ratios.
Results

Data Selection
The literature search yielded 102 references. Twenty-seven publications were excluded for various reasons (seven were review articles, 14 used animal models, four were case reports and two were metaanalyses). The full text of 75 articles was selected as potentially relevant and retrieved for a more detailed assessment. We excluded 44 studies for not detailing the clinical data or therapy response of the patients. The procedure used to select the clinical trials is shown in Fig. 1 . Thirty-one articles 6, reporting clinical trials of bone marrow stem cell-based therapy were ultimately selected for the meta-analysis.
Characteristics of the Patients and Clinical Trials
The clinical characteristics of the patients tion, rest pain and gangrene. The major causes of PAD are atherosclerosis obliterans (ASO) and thromboangiitis obliterans (TAO) 1) . Critical limb ischemia (CLI) is the most severe stage of PAD, in which plaque formation affects the arteries of critical limbs. Over time, plaque deposits narrow the arteries, thus limiting the flow of oxygen-rich blood, thereby inducing pain and resulting in the development of gangrene with the potential need for amputation. Surgical or endovascular revascularization is the only treatment option in cases of severe disease, although up to 30% of patients are not candidates for such procedures 2) . The rate of amputation among patients who do not qualify for revascularization is 30-50% at one year 2, 3) , and approximately 52% of diabetic patients with CLI die during follow-up after four to five years 4, 5) . In recent years, the development of cell therapy has provided new treatment approaches for such patients. In 2002, Tateishi-Yuyama 6) et al. first transplanted autologous bone marrow stem cells in patients with limb ischemia and reported the efficacy of this therapy based on a statistical analysis, providing new hope for patients.
It has also been reported that bone marrow stem cells function via different mechanisms 7) . For example, transplanted cells migrate to the ischemic endothelial surface, where they improve the density of capillaries and ameliorate the blockage of arteries, primarily by secreting VEGF, which exhibits paracrine effects. In addition, transplanted cells excrete different cytokines in order to regulate the microenvironment, consequently alleviating symptoms through their immunosuppressive role promoted by CD14 ＋ monocytes. Furthermore, bone marrow stem cells acquire myogenic and endothelial properties, with a therapeutic effect based on their capacity for differentiation 7) . Although the specific mechanisms of new therapies remain uncertain, an increasing number of clinical trials of bone marrow stem cells have demonstrated the critical role of these cells in PAD treatment, and a treatment method based on these principles has recently been entered into a phase Ⅲ clinical trial 8) . In the present study, we collected and analyzed data and performed a meta-analysis of clinical trials in order to estimate the therapeutic efficacy of bone marrow stem cells in treating PAD, especially CLI.
Methods
Literature Search
The authors searched for relevant studies of clinical trials published before October 30, 2013 using the search terms "autologous bone marrow stem cells," "peripheral arterial disease" and "critical limb isch- Table 2 . Some of the studies reported detailed data regarding the patients' disease stage before and after stem cell therapy that could be analyzed with SPSS 23, 24) , although the majority of the selected studies only described the disease stage before therapy. Using the chi-squared test, we found no significant differences between the treatment groups and control groups in terms of the disease stage (P＞0.05) based on the available data.
ABI
The ankle-brachial index (ABI) is an efficient tool for objectively documenting the presence of lower extremity PAD. Data for the ABI were available in 20 trials 6, 9-14, 17, 18, 21-27, 31, 33-35) . We separated the trials into two groups: the RCT group and the non-RCT group. With respect to the efficacy of stem cell therapy compared with the control therapy, the estimated pooled MD for the five RCTs 6, [21] [22] [23] [24] showed a significant increase in the ABI using an inverse variance model (MD 0.14, recruited for the therapies are summarized in Table 1 . Men dominated all of the trials, and the average age of included patients ranged from a minimum of 42 to a maximum of 78 years. Diabetes and hypertension (HT) were the most frequent causes of PAD, followed by smoking; these factors are cited in Table 1 . Regarding the geographic distribution, 18 trials were performed in Asian countries (especially Japan, India and China), eight trials were performed in European countries (Belgium, Italy, Slovakia, Germany, the Czech Republic and Turkey) and five trials were performed in North America (Cuba, USA). In these studies, autologous bone marrow mononuclear and mesenchymal stem cells were used for treatment, with a cell dose ranging from 10 6 to 10
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. The route of administration of cells was primarily intramuscular (IM) and intra-arterial (IA). These characteristics are outlined in Table 1 .
We also collected data regarding the CLI category determined according to Fontaine stem cells after four to eight, 12 and 24 weeks of follow-up ( Fig. 2A) in the RCT group. In addition, we compared the ABI values obtained at different stages 95% CI 0.07-0.21, P = 0.0001; MD 0.14, 95% CI 0.00-0.27, P = 0.05; MD 0.14, 95% CI 0.10-0.19, P ＜0.00001) among the PAD patients treated with The random-effects meta-analysis model (Mantel-Haenszel method) was used. MD, mean difference. Each trial is represented by a square, the center of which gives the MD for that trial. The size of the square is proportional to the information in that trial. The ends of the horizontal bars denote the 95% CI. The black diamond gives the overall MD for the combined results of all trials.
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TcO2
In the RCT group, the transcutaneous oxygen tension (TcO2) values significantly increased after four to eight and 24 weeks (MD 6.89, 95% CI 6.17-7.62, P ＜ 0.00001; MD 20.35, 95% CI 12.51-28.19, P ＜ 0.00001), but not 12 weeks (MD 1.95, 95% CI −7.41-11.30, P = 0.68) (Fig. 3A) . Data regarding the TcO2 values after 12 and 48 weeks were reported in only one study and were not appropriate for a meta-analysis 16, 29) . Meanwhile, the TcO2 values increased in the six selected trials in the non-RCT group 12, 13, [16] [17] [18] 29) after four to eight weeks of cell therapy (MD 11.90, 95% CI 2.37-21. 43 , P = 0.01), but not 24 weeks of before and after stem cell treatment in order to assess the effects of therapy in the non-RCT group. The estimated pooled MD for the 15 trials 9-14, 17, 18, 25-27, 31, 33-35) showed a significant increase in the ABI after 12, 24 and 48 weeks of follow-up (MD 0.12, 95% CI 0.07-0.16, P＜0.00001; MD 0.14, 95% CI 0.10-0.17, P＜ 0.00001; MD 0.12, 95% CI 0.02-0.23, P = 0.02) (Fig. 2B) . After four to eight weeks, the ABI values were not significantly increased (MD 0.06, 95% CI −0.03-0.16, P = 0.21) in the other selected trials in the non-RCT group. The random-effects meta-analysis model (Mantel-Haenszel method) was used.
Figure 3B
A B cacy of stem cell therapy. In the patients treated with cell therapy, the level of pain (on a 0-10 scale) significantly decreased (MD −3.36, 95% CI −5.53-−1.20, P = 0.002; MD − 3.53, 95% CI − 5.65-− 1.40, P = 0.001) in the analysis of the 11 studies in the non-RCT group 9-11, 13, 17, 20, 25, 26, 29, 31, 35) after four to eight and 24 weeks, although no significant decreases were observed after 12 weeks (MD −1.38, 95% CI −4.00-1.25, P = 0.30) (Fig. 4B) . In terms of the efficacy of cell therapy (MD 12.82, 95% CI − 1.65-27.29, P = 0.08) (Fig. 3B) .
Pain (Visual Analogue Scale, VAS)
The assessment of ischemia in patients with peripheral arterial disease typically relies on the use of objective surrogate indexes, and the disease burden essentially derives from the level of pain. We collected more subjective symptoms (pain) to examine the effi- The random-effects meta-analysis model (Mantel-Haenszel method) was used.
Figure 4B
A B AFS rate (OR 22.33, 95% CI 4.14-120.5, P = 0.0003) (Fig. 5) .
Safety Issues
We analyzed the incidence of severe adverse events in the selected studies. The majority of adverse events were associated with hospitalization for disease process-related complications, not complications related to cell therapy, including pain in the extremities and gastrointestinal disorders that were unrelated to the cell therapy. The adverse events are listed in Table 3 according to the known data, which were obtained from 13 selected studies 6, 9, 11, 18, 21, 25, 26, 30-33, 35, 36) . As the data show, a total of six of 484 patients died during follow-up, four patients experienced recurrence and one patient developed a fever after undergoing treatment. The follow-up period ranged from two months to two years, which is expected to have induced variation in the results.
Limitations of our Meta-Analysis Publication Bias
We cannot eliminate the potential for publication bias, which may have affected the results of the present meta-analysis. Negative trial outcomes are often not published, which may make our efficacy assessment insufficient. In addition, the inclusion of Chinese language studies may have provided another source of publication bias. Furthermore, we selected studies that applied bone marrow stem cell therapies using bone marrow mesenchymal stem cells and bone marrow mononuclear cells, which may contain distinct cell populations. stem cell therapy compared with the control therapy, the estimated pooled MD for six RCT trials 6, 15, [21] [22] [23] [24] showed a significant decrease in pain using an inverse variance model (MD − 1.37, 95% CI − 1.69-− 1.04, P ＜ 0.00001) following treatment with stem cells after 24, but not four to eight weeks or 12, weeks of followup in the RCT group (Fig. 4A) (MD − 0.01, 95% CI − 1.44-1.43, P = 0.99; MD − 1.84, 95% CI − 4.11-0.44, P = 0.11).
Amputation-Free Survival (AFS)
The Trans-Atlantic Inter-Society Consensus (TASC Ⅰ/Ⅱ) suggested that the combined endpoint of amputation-free survival (AFS) is the best outcome measurement for assessing patients with CLI 39) . Using the data obtained from the long-term clinical trials, we compared the 1-year and 3-year amputation-free survival rates between the stem cell therapy groups and the control groups.
Information regarding the 1-year AFS was available in three trials 19, 37, 38) comprising 162 patients (88 of whom received stem cell therapy). The three trials reported higher survival rates for the patients treated with stem cell therapy than those in the control group. The estimated pooled OR for the three trials showed a significant improvement in the one-year amputationfree survival for the patients receiving stem cell therapy (OR 8.05, 95% CI 3.58-18.08, P ＜ 0.00001). Meanwhile, information for the 3-year survival rate was available for 97 patients (51 of whom received stem cell therapy). The results of the pooled analysis showed that the patients in the stem cell therapy group exhibited a significantly improved three-year The random-effects meta-analysis model (Mantel-Haenszel method) was used.
Figure 5
cells, has been shown to increase the rate of neo-vascularization of ischemic tissue 12, [40] [41] [42] [43] . Several clinical studies have shown that a variety of stem cell types delivered locally via the intramuscular route or systemically via the intra-arterial route into ischemic tissue have several therapeutic benefits [44] [45] [46] . We herein presented a comprehensive review and performed a meta-analysis of bone marrow stem cell therapy trials in patients with peripheral arterial disease, particularly CLI. A total of 1,214 patients without options for revascularization received treatment in these trials. The analysis, in which the RCTs and other trials (non-RCTs) were classified into two groups, showed that cell therapy significantly improves the ABI, TcO2 and AFS values and reduces rest pain. Regarding the efficacy of stem cell therapy, the ABI values significantly increased (P ＜ 0.05) after 12, 24 and 48 weeks of therapy in both the non-RCT and RCT groups, but not after four to eight weeks of therapy in the non-RCT group. In addition, the TcO2 values increased after four to eight and 24 weeks of therapy in the RCT group (P ＜ 0.001) and after four to eight weeks of therapy in the non-RCT group (P = 0.01), but not after 12 weeks of therapy in the RCT group or after 24 weeks of therapy in the non-RCT group. Meanwhile, pain was significantly reduced (P ＜ 0.05) after four to eight and 24 weeks of
Robustness
This meta-analysis was performed using highquality studies (randomized controlled studies) and low-quality trials (non-controlled trials). We analyzed the studies separately using the Review Manager Version 5.0 software program. Given that all of the studies applied different indexes, we selected surrogate objective endpoints (secondary endpoints) included in the trials, such as the ABI, TcO2, AFS and level of pain assessed according to VAS. We excluded endpoints without the same criteria.
Discussion
The incidence of CLI is estimated to be almost 500 to 1,000 per million individuals each year. Approximately 50% of patients with CLI undergo amputation within 6-12 months, and approximately 15% of those patients lose the contralateral leg within two years, a condition for which the one-year mortality rate is as high as 20%, rising to 70% and 100% at five and 10 years, respectively 15) . Patients who suffer from pain due to CLI are in urgent need of novel therapeutic strategies to preserve their limbs. Transplantation of autologous bone marrow stem cells, which include both bone marrow mononuclear cells and bone marrow mesenchymal Despite the high degree of heterogeneity observed in the current study, this novel therapeutic method may ultimately improve the prognosis of PAD patients, particularly those with CLI. In the present meta-analysis, we confirmed that stem cell therapy is generally effective, resulting in significant changes in each endpoint after treatment.
Conclusion
We herein demonstrated the significant efficacy of autologous bone marrow cell therapy for treating PAD in a meta-analysis, including outcomes showing an increase in ABI and TcO2, a decrease in pain and a longer AFS. These outcomes should be interpreted carefully, as the duration of follow-up was insufficient and the number of available randomized controlled studies was too limited to enable us to confirm the efficacy and safety of this novel strategy for treating PAD. Larger multi-center randomized trials should be conducted in order to verify the effectiveness of this therapy in the near future. The outcomes of our systematic review are expected to encourage further studies of the specific mechanisms by which these cells repair tissues and promote neovascularization, as well as stimulate further research focused on identifying signal pathways associated with the pathological systems of CLI. Such innovations should be expanded and their efficacy verified in multi-center pilot trial studies in order to obtain further evidence of their effectiveness as therapeutic options. therapy in the non-RCT and RCT groups, but not after four to eight weeks or 12 weeks of therapy in the RCT group.
The results of the data analysis showed no major differences between the non-RCT and RCT groups, with an overall trend toward an increase in the ABI and TcO2 values and a decrease in pain. The longterm clinical trials demonstrated improvements in the AFS rate after therapy with bone marrow stem cells (one-year AFS, P ＜0.00001; three-year AFS, P =0.0003). Therefore, the meta-analysis showed the potential efficacy of autologous bone marrow mononuclear cell therapy in treating peripheral arterial disease.
The inclusion of high-quality randomized controlled trials in a meta-analysis allows for more reliable results to be obtained. In the present study, we selected randomized controlled and non-controlled studies due to differences in clinical standards among the studies and the limited number of high-quality trials. Compared with a previous meta-analysis 1) , our meta-analysis included only one paper reviewed in that investigation and contained more relevant new studies published between 2009 and 2013, including recent research carried out in China. In addition, we collected long-term follow-up data for the endpoint AFS in order to assess the efficacy of autologous bone marrow stem cell therapy in patients with peripheral arterial disease; this parameter has also been reviewed in three other meta-analyses, all of which showed the same conclusions [47] [48] [49] . Furthermore, we analyzed known safety issues and found that this novel treatment is relatively safe, consistent with the results of previous meta-analyses [47] [48] [49] , although the duration of follow-up differed in the selected studies, which makes it difficult to draw the conclusion that stem cell therapy is well tolerated. Therefore, larger, placebo-controlled, randomized multi-center trials are needed to confirm the safety and efficacy of this method.
The present meta-analysis showed a high rate of heterogeneity. Possible reasons for this phenomenon are as follows. All of the trials were either randomized controlled or non-controlled, and we cannot guarantee the quality of data without information for random and blind allocations. In addition, the patients involved might be in different stages of CLI. As in our review, we included patients diagnosed with Rutherford 4 to 6 disease, and the majority of studies provided limited information regarding this issue, which may have led to significant differences between different groups in certain endpoints, thus affecting the weight of the studies, although we found no differences in regard to the disease stage among the available trials. Moreover, differences in the number of 
